منابع مشابه
NEW DRUG APPROVALS Opdivo for Melanoma
NEW DRUG APPROVALS Opdivo for Melanoma Nivolumab injection (Opdivo, BristolMyers Squibb) has received the FDA’s accelerated approval for the treatment of patients with unresectable or metastatic melanoma that has progressed after treatment with specific medications. Nivolumab is a monoclonal antibody that binds to the programmed death-1 (PD-1) receptor and blocks its interaction with ligands PD...
متن کاملNEW DRUG APPROVALS Kybella for Submental Fat
NEW DRUG APPROVALS Kybella for Submental Fat Deoxycholic acid (Kybella, Kythera Biopharmaceuticals Inc.) has received FDA approval to treat moderate-to-severe fat below the chin, called submental fat. The product is not approved or recommended to treat fat outside of the submental area. Kybella is identical to the deoxycholic acid produced in the body, which helps the body absorb fats. A cytoly...
متن کاملNEW DRUG APPROVALS Farydak for Multiple Myeloma
NEW DRUG APPROVALS Farydak for Multiple Myeloma The FDA has approved panobinostat (Farydak, Novartis) to treat multiple myeloma (MM), which kills more than 10,000 mostly older Americans a year. Panobinostat inhibits the activity of histone deacetylases, which may slow the overdevelopment of plasma cells or cause these cells to die. Panobinostat is intended for patients who have received at leas...
متن کاملNEW DRUG APPROVALS Dalvance for Skin Infections
NEW DRUG APPROVALS Dalvance for Skin Infections The FDA has approved dalbavancin (Dalvance, Durata Therapeutics) to treat adults’ acute bacterial skin and skinstructure infections (ABSSSIs) caused by certain susceptible bacteria, such as Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains) and Streptococcus pyogenes. Administered intravenously, Dalvance is...
متن کاملNEW DRUG APPROVALS Repatha for High Cholesterol
NEW DRUG APPROVALS Repatha for High Cholesterol The FDA has approved evolocumab injection (Repatha, Amgen) for some patients who are unable to control their low-density lipoprotein-cholesterol (LDL-C) with current treatment options. Evolocumab, the second approved proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, is indicated for use in addition to diet and maximally tolerated st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Drug Discovery
سال: 2019
ISSN: 1474-1776,1474-1784
DOI: 10.1038/d41573-019-00177-7